Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and hyperglycemia
Resources GLP-1 Agonists
No claims are made regarding enhancement, pain, performance, or functional results
GoodRx Effectiveness Comparison Research shows that Rybelsus 14 mg daily provides similar blood sugar control to Ozempic 0.5-1 mg weekly
HbA1c Once-weekly subcutaneous administration of tirzepatide dose-dependently reduced HbA1c levels across all studies using the combination of GLP-1 and GIP.2, 3, 4, 5, 6 The results of the SURPASS-2 study showed that individuals who had established T2DM and were treated with tirzepatide at doses ranging from 5 to 15 mg for a duration of 40 weeks experienced a reduction in HbA1c levels ranging from 2.09% to 2.46%.3 This reduction was higher than that observed in individuals treated with semaglutide (1 mg), who experienced a 1.86% reduction in HbA1c levels.3 Similarly, in the SURPASS-3 study, individuals who received tirzepatide at doses ranging from 5 to 15 mg for 52 weeks experienced a reduction in HbA1c levels ranging from 1.93% to 2.37%, which was higher than that observed in individuals treated with insulin degludec, who experienced a decrease of 1.34%.4 In Japanese individuals with T2DM, after 52 weeks of treatment, tirzepatide at doses ranging from 5 to 15 mg reduced HbA1c levels by 2.4%3.02%.27 Additionally, in this population, tirzepatide was more effective in controlling blood glucose levels than dulaglutide administered once weekly at a dose of 0.75 mg.27 Collectively, tirzepatide elicited a much stronger HbA1c-lowering effect in all the SURPASS programs compared with placebo or active comparators, including GLP-1 RA and basal insulin.2, 3, 4, 5, 6, 27 Table 1 summarizes the main findings of the SURPASS programs and details the HbA1c lowering efficacy of tirzepatide
One 2017 study by John Hopkins Bloomberg School of Public Health suggested: Helping an adult lose weight leads to significant cost savings at any age. Mayo Clinic research from 2025 suggests that losing weight may reduce the risk of T2D
